Launch of Major Product Expected to Significantly Drive Performance Growth

HONG KONG, March 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 12, 2025, the company's serum-free iterative rabies vaccine has recently obtained the production license for serum-free rabies vaccine and will submit for market registration. This product is expected to be the first serum-free rabies vaccine on the global market, marking a significant technological breakthrough for AIM Vaccine and further solidifying the company's global leadership position in the rabies vaccine field.

AIM Vaccine stated that the results of the completed blinded Phase III clinical study indicate that this serum-free iterative rabies vaccine has good safety, immunogenicity, and immune durability, fully meeting the preset evaluation criteria for clinical trials.

There are two types of rabies vaccines: one is a serum-based rabies vaccine, and the other is a serum-free rabies vaccine. Currently, no serum-free rabies vaccine has been registered for market. The mainstream rabies vaccines sold on the market, such as Vero cell rabies vaccines and diploid rabies vaccines, are all serum-based.

AIM Vaccine introduced that the serum-free iterative rabies vaccine is entirely different from the currently available serum-containing Vero cell rabies vaccine and serum-containing diploid rabies vaccine; it is an upgraded product. The residual animal serum in vaccine products is one of the significant factors leading to adverse reactions, such as allergies, in vaccinated populations. The serum-free iterative rabies vaccine developed by the company does not contain animal serum, significantly improving safety and reducing the likelihood of adverse reactions.

As of now, there has been no serum-free rabies vaccine approved for market worldwide, and this product is expected to be the first to be launched.

Additionally, according to the "National Regulation for the Rabies Exposure Prophylaxis (2023 Edition)" established by the National Disease Control and Prevention Administration (NDCPA) and the National Health Commission of PRC(NHC), outpatient clinics for rabies vaccinations are required to be equipped with at least two different types of rabies vaccines. With its technological advantages, the serum-free iterative rabies vaccine is expected to become the preferred choice for vaccination institutions.

According to professional analysis, this innovative major product vaccine, which will soon be the first of its kind globally, is expected to bring significant growth momentum to AIM Vaccine. The research report from Fosun International Securities¹ believes that AIM Vaccine has completed its iterative upgrades from Vero cell vaccines to diploid cell vaccines, serum-free vaccines, and then to mRNA vaccines, demonstrating its capability to grasp market trends and meet clinical needs. This strategy not only enhances the company's market share but also significantly improves its product pricing power and profitability.

It is forecasted that the sales of the company's rabies vaccine product line will rapidly grow from RMB 2.65 billion in 2023 to over RMB 15 billion. With its first-mover advantage in serum-free rabies vaccines and other fields, AIM Vaccine is expected to capture more than one-third of the global market value share.

Regarding the company's growth potential, the Fosun International Securities research report indicates that with the rollout of several high-value products in the coming years, AIM Vaccine's revenue and profitability are expected to recover strongly, driving a significant increase in its valuation. For investors seeking to enter the vaccine industry, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it an attractive investment choice.

Note 1: http://www.aastocks.com/tc/stocks/news/glh-news/GLH1832345L/1